Answers are grounded in this paper and cite their sources.
We were able to radiolabel the rhTSH superagonist analogue TR1401 with (99m)Tc efficiently with retention of in vitro and in vivo binding capacity to TSHR. The relative role of such novel radiopharmaceutical versus (131)I scanning of thyroid cancer will require future histopathologic and clinical studies, but it may open new perspectives for presurgical staging of thyroid cancer, and diagnosis of radioiodine negative local relapses and/or distant metastases.
No takes yet. Share an insight, caveat, or question.
Galli et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: